Sophia Genetics raises funds for USA growth

The Swiss start-up with a research & development centre based in the Izarbel Technology Park has raised $77 million, in particular to boost its presence in the USA.

Founded in Switzerland in 2011 by Bayonne-born Jurgi Camblong and Swiss partners Pierre Hutter and Lars Steinmetz, Sophia Genetics developed a procedure which enables hospitals to analyse patients’ genetic data generated by DNA sequencing.

Using the artificial intelligence of its Sophia DDM platform, the company run by Jurgi Camblong decodes genetic data generated by hospitals the world over and enables them to identify characteristic changes in genetic diseases, thus leading to faster diagnosis.

The company, which has become the world leader in data-based medicine, employs almost 200 people (50% of whom are based in the headquarters in Lausanne, Switzerland) and opened a research & development centre at the Izarbel Technology Park in March 2018, in order to develop its technology. 

Since its creation, the company has carried out several capitalisations and with this raising of $77 million announced in early January, Sophia Genetics will have raised a total of $140 million. Its Sophia DDM platform is currently used by around 850 hospitals in 77 countries.

With these new funds, Sophia Genetics is hoping to increase the number of hospitals using its technology, in addition to developing its US presence in Boston, by recruiting new staff to boost its American expansion.

Website: https://www.sophiagenetics.com/home.html